price close busi dec
catalyst beyond
busi sinc last edit key event come user-friendli format
sinc novemb edit see day see report solid
phase data rimegep migrain acut treatment orally-dissolv tablet see
top-lin long-term safeti data rimegep see rais capit
announc accept lumateperon schizophrenia new drug applic
nda intrigu top-lin interim data open label-switch studi see
sage zulresso intraven brexanolon post-partum depress
action date push final rem see also initi
coverag see see disappoint pediatr
tourett syndrom news valbenazin see make report user-
friendli within compani catalyst sub-sect company/competitor-
driven event tabl catalyst tabl
nuplazid parkinson diseas psychosi sale outlook key
besid outlook could updat us meet fda major
depress disord mdd inadequ respons program pimavanserin
aldr eptinezumab migrain prevent biolog licens applic file
epti iv anti-cgrp biolog other approv subcutan
troriluzol signal spinocerebellar ataxia rimegep nda file
top-lin result assess troriluzol signal year sca could come time
expect file nda rimegep acut treatment migrain
partner alkerm expect file vumer multipl sclerosi competitor nv
spinal muscular atrophi type could approv
iv dex data agit alzheim ad schizophrenia bipolar disord
phase pk/pd data iv dex could come bridg bioavailabilti pk
data agit ad schizophrenia/bipolar disord could come
lumateperon interim data behavior disturb associ w/ dementia
interim analysi phase could come dcf scenario
tourett misstep ingrezza outlook key expect report data
phase studi classic congenit adren hyperplasia
phase pivot data zulresso action date
investor keenli await oral data read mdd
fda meet vy-aadc pd gene therapi phase patient dose
type meet import recent setback pathway see
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
tabl potenti catalyst page
result potenti financi outlook
potenti meet fda discuss next step pimavanserin mdd
initi two phase trial pimavanserin mdd
potenti enrol complet pimavanserin phase
hire chief offic cfo
inadequ respons
antidepress
inadequ respons
antidepress
begin enrol phase trial mdd
top-lin data phase ascend trial axs-
top-lin result phase trial
potenti initi phase trial epidiolex
potenti start pivot studi evenamid
top-line result allergan rapastinel phase trial
potenti top-lin data phase star studi newron
top-line result phase trial minerva mdd
updat neuralstem
adjunct therapi estim studi complet date jan-
announc todd young
employ end elena ridloff serv
estim primari complet date estim
fda adcom panel jointli vote
benefit-risk profil adequ support approv
parkinson psychosi
aldr appoint dr eric carter interim
aldr announc ms elisabeth sandov
employ end
expect last per earn press
teva receiv approv price product
aimovig emgal
other monthli
lilli receiv approv price product
aimovig teva ajovi
receiv approv aimovig set
list price per year aimovig
first anti-cgrp product approv fda
approv inject set price
potenti initi phase trial
develop
potenti detail long-term data eptinezumab phase studi
hire chief medic offic
hire chief commerci offic
potenti updat eptinezumab subcutan formul
potenti ex-u partner eptinezumab
initi allergan atogep phase studi
launch ramp teva ajovi fremanezumab
launch ramp lilli emgal galcanezumab
track commerci progress amgen/novarti aimovig erenumab
top-line result long term extens phase assess drug signal one
year troriluzol
bioshin wholli own subsidiari plan submit first ind
applic china food drug administr cfda
initi second random control phase trial troriluzol
end
initi phase trial troriluzol
potenti nda file rimegep
updat eu strategi rimegep
result long-term safeti studi rimegep
addit data phase studi rimegep studi
addit data proof concept trial anxieti
potenti updat on-going phase trial
initi phase trial genervon
potenti nda file allergan ubrogep
initi allergan atogep phase studi
result phase fortitude- trial reldesemtiv
acut treatment
acut treatment
acut treatment
acut treatment
acut treatment
prevent migrain
acut treatment
estim primari complet date estim
receiv feedback ema outlin
sever potenti pathway approv rimegep per
file updat
announc initi result open-label
long-term safeti studi rimegep estim primari
complet date estim studi complet date
upcom scientif meet report
posit top-lin result trial
announc dose first patient
per slide ioni present date
discuss european medicin agenc path forward
launch ramp teva ajovi fremanezumab
launch ramp lilli emgal galcanezumab
track commerci progress amgen/novarti aimovig erenumab
perform itf pharma tiglutik riluzol oral suspens
initi phase trial ibudilast
conduct addit analys data phase studi neuraltu
close transact increas stake samsung bioepi
initi phase studi
initi phase evolv studi aducanumab
end
end
potenti nda file vumer
end multipl sclerosi
teva receiv approv price product
aimovig emgal
other monthli
lilli receiv approv price product
aimovig teva ajovi
receiv approv aimovig set
list price per year aimovig
first anti-cgrp product approv fda
approv inject set price
itf pharma receiv approv expect
launch
receiv posit feedback fda
phase plan ibudilast al
asset acquir
studi design assess clinic relev
estim primari complet date estim
global licens collabor agreement alkerm
estim studi complet date phase trial
result potenti busi updat
vixotrigin initi phase program trigemin neuralgia
biogen/univers pennsylvania sma gene therapi potenti enter
earn call said fda place ind
clinic hold updat call
detail result phase studi alzheim patient
detail data phase trial dapirolizumab pegol upcom medic
potenti updat phase studi healthi volunt
impact roch ocrevu multipl sclerosi franchis
potenti busi develop activity/acquisit
potenti submiss market author applic shanghai
greenvalley pharmaceut china
novartis/avexi initi pediatr comer sma type
later
late earli
mild moder
type
eisai/biib present fuller data aaic meet chicago
ctad barcelona sub-group analys
present initi posit top-lin data
earn press releas date biogen
announc acquir alg-
alivegen inc
receiv royalti ocrevu
enrol approxim patient six month
year age qualifi trial
time gene therapi
possibl gener competit novarti gilenya fingolimod
potenti approv launch novartis/avexi us
potenti approv launch novartis/avexi japan
top-lin result phase studi firdaps
sma type
updat on-going pivot trial roch s/ptct
sma type
effect generic copaxon brand ms product
potenti path forward sma type
updat on-going trial
top-lin data phase pk/pd studi dexmedetomidin iv
end
agit alzheim
novarti announc fda accept nda
file prioriti review
novarti initi submiss mid-septemb anticip
complet year end
type
type
first patient dose phase poc studi
first patient dose bridg bioavail ba pk studi
initi phase studi checkpoint inhibitor
initi phase poc studi
potenti data readout bridg bioavail ba pk studi
interim analysi intra-cellular therapi phase trial
interim analysi phase trial lumateperon
initi clinic program lumateperon depress disord
begin enrol phase trial mdd
agit alzheim
diseas schizophrenia
agit alzheim
diseas schizophrenia
associ dementia
associ dementia
initi phase trial restorbio combin rapalog
parkinson diseas
data readout phase trial bipolar depress
announc accept ind
neoadjuv proof mechan trial initi
estim primari complet date estim
last per earn call
estim primari complet date estim
fda adcom panel jointli vote
benefit-risk profil adequ support approv
end
potenti snda approv allergan vraylar cariprazin
top-line result phase trial minerva mdd
top-line result allergan rapastinel phase trial
initi phase trial acadia pimavanserin adjunct therapi
complet phase trial novel inhibitor
potenti preliminari sale result
data phase studi
result potenti busi updat
data pivot phase studi phase extens studi
estim studi complet date phase trial pk/pd spruce
initi larger clinic studi emalex bioscienc ecopipam
potenti initi phase trial obseva linzagolix
initi data first two patient axov scienc phase dose
escal studi sunrise-pd axo-lenti-pd
potenti top-lin data phase trial lundbeck/prexton foliglurax
updat allergan uliprist acet
announc accept snda fda
pdufa action date may
compani expand studi includ addit
patient optim dose flexibl conveni
axon announc patient dose trial
allergan receiv complet respons letter
us fda abl approv uliprist acet
nda current form allergan plan meet fda
discuss comment next step
begin enrol phase trial mdd
initi phase trial mdd patient co-morbid
complet single-ascend dose trial healthi
initi phase multipl ascend dose trial
top-lin result phase pivot trial
data readout phase target engag studi
data readout phase multipl ascend dose trial
data readout phase trial bipolar depress
top-lin data phase ascend trial axs-
estim primari complet date estim
estim primari complet date estim
announc fda extend zulresso
pdufa date final rem
fda adcom panel jointli vote
benefit-risk profil adequ support approv
top-line result allergan rapastinel phase trial
potenti snda approv allergan vraylar cariprazin
initi phase trial acadia pimavanserin adjunct therapi
top-line result phase trial minerva mdd
data part phase magnolia studi marinu
full data phase amarylli studi
updat neuralstem
announc accept snda fda
pdufa action date may
announc posit result part
announc posit result interim
analysi amarylli studi
formal guidanc scientif advic work parti sawp
european medicin agenc ema azeliragon
multi-region phase studi
updat clinic develop pathway azeliragon
type meet fda discuss program detail vy-aadc
updat type meet fda vy-aadc program
long-term data vy-aadc phase cohort
enrol statu phase trial vy-aadc
hire chief medic offic
initi data first two patient axov scienc phase dose
escal studi sunrise-pd axo-lenti-pd
compani report clinicaltri gov canaccord genuiti estim updat
late octob receiv addendum
fda juli written respons fda
inform compani although data phase
trial may support safeti efficaci vy-aadc
could consid bla review fda current
consid phase trial earli phase exploratori studi
announc resign bernard
ravina continu serv clinic advisor
last earli expect end
previous guid rang per
earn releas
axon announc patient dose trial
result potenti financi outlook
estim studi complet date phase open-label safeti efficaci
studi pimavanserin
potenti meet fda discuss next step pimavanserin
initi two phase trial pimavanserin mdd
potenti enrol complet pimavanserin phase
potenti data readout pimavanserin phase studi
estim studi complet date phase open-label trial
initi phase trial trofinetid
potenti enrol complet pimavanserin phase advanc
potenti interim data-readout phase trial harmoni
estim studi complet date phase trial harmoni
estim studi complet date phase open-label safeti
toler studi pimavanserin
potenti nda file trofinetid
hire chief offic cfo
treatment adult
parkinson diseas
inadequ respons
antidepress
inadequ respons
antidepress
agit aggress
adjunct therapi estim primari complet date
adjunct therapi estim studi complet date jan-
adjunct therapi
acadia enter exclus licens
agreement develop
commerci trofinetid rett syndrom
adjunct therapi estim studi complet date jun-
adjunct therapi estim primari complet date
announc todd young
employ end elena ridloff serv
suffici least next month per file
begin enrol phase trial mdd
top-lin data phase ascend trial axs-
top-lin result phase trial
estim studi complet date syneurx naben phase trial
estim studi complet date syneurx naben phase trial
potenti initi phase trial epidiolex
potenti start pivot studi evenamid
top-line result allergan rapastinel phase trial
potenti top-lin data phase star studi newron
top-line result phase trial minerva mdd
top-lin result phase elev trial vistagen
top-lin result phase trial minerva/mitsubishi tanab
potenti file nda schizophrenia
potenti fda advisori committe meet lumateperon
estim studi complet date allergan phase trial
lumateperon fda action date schizophrenia
estim studi complet date phase debut studi lundbeck lu
estim studi complet date anavex phase trial
estim studi complet date syneurx naben phase trial
estim primari complet date estim
fda adcom panel jointli vote
benefit-risk profil adequ support approv
request prioriti review base track
design grant lumateperon treatment
announc fda accept nda
lumateperon treatment schizophrenia
result two phase trial minerva seltorex
patient mdd adjunct therapi
potenti approv janssen esketamin nasal spray us fda
estim studi complet date phase trial sunovion
estim studi complet date phase trial mediti pharma mp-
estim studi complet date phase trial astrazeneca
updat neuralstem
potenti initi phase trial reviva pharmaceut
develop reviva pharmaceut
janssen announc submiss esketamin
nasal spray us fda
parkinson psychosi
adjunct therapi estim primari complet date
last updat compani clinicaltri gov
compani report clinicaltri gov canaccord genuiti estim updat
ind file
payment teva approv bla eptinezumab
initi first-in-human studi
potenti launch eptinezumab
potenti data first-in-human studi
potenti detail long-term data eptinezumab phase studi
hire chief medic offic
hire chief commerci offic
potenti updat eptinezumab subcutan formul
potenti ex-u partner eptinezumab
initi allergan atogep phase studi
potenti data phase trial
launch ramp teva ajovi fremanezumab
end
launch ramp lilli emgal galcanezumab
track commerci progress amgen/novarti aimovig erenumab
compani report clinicaltri gov canaccord genuiti estim updat
monoclon antibodi target pituitari
adenyl cyclase-activ
prevent migrain
per aldr european patent settlement global licens
agreement teva
aldr appoint dr eric carter interim
aldr announc ms elisabeth sandov
employ end
expect last per earn press
result avail year end present
medic confer
teva receiv approv price product
aimovig emgal
other monthli
lilli receiv approv price product
aimovig teva ajovi
receiv approv aimovig set
list price per year aimovig
first anti-cgrp product approv fda
approv inject set price
top-line result long term extens phase assess drug signal one
year troriluzol
bioshin wholli own subsidiari plan submit first ind
applic china food drug administr cfda
initi second random control phase trial troriluzol
end
initi phase trial troriluzol
potenti nda file rimegep
initi phase trial
pdufa action date al
futil analysi phase trial troriluzol mild moder
top-line data phase trial
potenti enrol complet trial troriluzol ocd
potenti enrol complet trial troriluzol gad
end
estim studi complet date phase trial troriluzol
addit data zydi oral dissolv tablet studi
initi phase trial
potenti top-line data phase trial rimegep prevent
potenti enrol complet trial troriluzol sca
acut treatment
mild moder
acut treatment
prevent migrain
acut treatment
acut treatment
prevent migrain
estim primari complet date estim
announc fda accept
nda file treatment al
initi trial phase trial success
announc enrol first patient
trial estim studi complet date
complet addit toxicolog phase trial
potenti approv launch
estim studi complet date phase trial troriluzol
potenti launch rimegep
updat eu strategi rimegep
result long-term safeti studi rimegep
addit data phase studi rimegep studi
addit data proof concept trial anxieti
potenti updat on-going phase trial
initi phase trial genervon
potenti nda file allergan ubrogep
estim studi complet date phase trial amylyx
initi allergan atogep phase studi
result phase fortitude- trial reldesemtiv
potenti nda approv lilli lasmiditan
mild moder
acut treatment
acut treatment
acut treatment
acut treatment
acut treatment
prevent migrain
acut treatment
acut treatment
announc fda accept
nda file treatment al
receiv feedback ema outlin
sever potenti pathway approv rimegep per
file updat
announc initi result open-label
long-term safeti studi rimegep estim primari
complet date estim studi complet date
upcom scientif meet report
posit top-lin result trial
announc dose first patient
suffici fund oper per file
per slide ioni present date
announc submiss nda
lasmiditan us fda
top-lin result phase studi brainstorm cell
potenti data phase trial
potenti launch allergan ubrogep
discuss european medicin agenc path forward
launch ramp teva ajovi fremanezumab
acut treatment
launch ramp lilli emgal galcanezumab
track commerci progress amgen/novarti aimovig erenumab
perform itf pharma tiglutik riluzol oral suspens
initi phase trial ibudilast
conduct addit analys data phase studi neuraltu
compani report clinicaltri gov canaccord genuiti estim updat
result avail year end present
medic confer
teva receiv approv price product
aimovig emgal
other monthli
lilli receiv approv price product
aimovig teva ajovi
receiv approv aimovig set
list price per year aimovig
first anti-cgrp product approv fda
approv inject set price
itf pharma receiv approv expect
launch
receiv posit feedback fda
phase plan ibudilast al
close transact increas stake samsung bioepi
initi phase studi
initi phase evolv studi aducanumab
end
end
potenti nda file vumer
estim studi complet date phase trial
end multipl sclerosi
result potenti busi updat
estim studi complet date phase trial
potenti result phase trial passport
potenti interim analys phase data aducanumab
potenti initi phase trial
potenti data phase trial
potenti exercis option acquir
sclerosi
potenti approv biosimilar adalimumab us
top-lin data phase trial aducanumab
potenti approv launch vumer
full data phase studi
end
asset acquir
studi design assess clinic relev
estim primari complet date estim
global licens collabor agreement alkerm
identifi alkerm announc
receiv payment review
announc enter
exclus option agreement acquir tm co ltd japan
per slide ioni present date
exercis option ioni develop
commerci base posit interim data readout
phase trial
biib/samsung bioepi announc accept bla
adalimumab biosimilar fda
estim studi complet date phase trial passport
estim studi complet date phase trial
data phase affin studi opicinumab
estim studi complet date phase trial natalizumab
associ
estim studi complet date phase affin trial
estim studi complet date phase trial tysabri eid
estim studi complet date phase trial eisai
estim studi complet date phase trial eisai
estim studi complet date phase trial
estim studi complet date phase spirit trial
estim studi complet date phase trial
estim studi complet date phase trial engag
estim studi complet date phase trial emerg
estim studi complet date phase studi
estim studi complet date phase trial
vixotrigin initi phase program trigemin neuralgia
biogen/univers pennsylvania sma gene therapi potenti enter
detail result phase studi alzheim patient
identifi announc
enrol complet trial
earn call said fda place ind
clinic hold updat call
eisai/biib present fuller data aaic meet chicago
ctad barcelona sub-group analys
present initi posit top-lin data
detail data phase trial dapirolizumab pegol upcom medic
potenti updat phase studi healthi volunt
impact roch ocrevu multipl sclerosi franchis
potenti busi develop activity/acquisit
potenti submiss market author applic shanghai
greenvalley pharmaceut china
novartis/avexi initi pediatr comer sma type
possibl gener competit novarti gilenya fingolimod
data novartis/avexi pre-symptomat sma type
potenti approv launch novartis/avexi us
potenti approv launch novartis/avexi japan
top-lin result phase studi firdaps
sma type
potenti approv launch novartis/avexi eu
later
late earli
estim studi complet date phase trial aztherapi
potenti studi complet novarti branaplam phase studi
potenti studi complet phase trial asclepio novarti
potenti studi complet phase trial asclepio ii novarti
complet novartis/avexi sma type phase trial strong
potenti approv merck kgaa nda mavenclad cladribin
mild moder
type
type
earn press releas date biogen
announc acquir alg-
alivegen inc
receiv royalti ocrevu
enrol approxim patient six month
year age qualifi trial
time gene therapi
american academi neurolog annual meet
novarti announc fda accept nda
file prioriti review
novarti initi submiss mid-septemb anticip
complet year end
novarti submit ema earli
enrol trial
fda accept nda merck kgaa mavenclad
estim studi complet date novartis/avexi us
estim studi complet date phase trial
estim studi complet date roche/ptct
sma type
estim studi complet date phase trial roch gantenerumab
estim studi complet date roche/ptct
sma type
potenti studi complet phase trial sakura novarti
estim studi complet date novartis/avexi eu
mild moder
type
type
top-lin result phase trial eisai
estim studi complet date phase trial cread roch
estim studi complet date phase trial solanezumab
estim studi complet date phase trial cread roch
estim studi complet date novartis/avexi pre-
symptomat sma type multi-n trial sprint
prodrom mild
prodrom mild
type
estim studi complet date phase trial roch gantenerumab
estim studi complet date phase trial roch gantenerumab
estim studi complet date phase trial janssen jnj-
estim studi complet date phase trial novarti
estim studi complet date phase trial novarti
patient enrol enrol approxim
patient copi less
six week age pre-symptomat time gene
updat on-going pivot trial roch s/ptct
sma type
effect generic copaxon brand ms product
potenti path forward sma type
updat on-going trial
type
type
compani report clinicaltri gov canaccord genuiti estim updat
top-lin data phase pk/pd studi dexmedetomidin iv
end
first patient dose phase poc studi
first patient dose bridg bioavail ba pk studi
potenti present data american societi
initi phase studi checkpoint inhibitor
initi phase poc studi
potenti data readout bridg bioavail ba pk studi
data phase poc studi
initi registr trial
data phase poc studi
potenti nda file
select next clinic candid
initi registr trial
potenti nda file
agit alzheim
agit alzheim
diseas schizophrenia
agit alzheim
diseas schizophrenia
agit alzheim
diseas schizophrenia
agit alzheim
diseas schizophrenia
pancreat cancer
pancreat cancer
announc accept ind
neoadjuv proof mechan trial initi
singl agent combo trial
mechan action combo trial
last least month
interim analysi intra-cellular therapi phase trial
associ dementia
estim studi complet date phase trial avanir
estim studi complet date phase trial avanir
top-lin result phase
estim studi complet date phase trial avanir
compani report clinicaltri gov canaccord genuiti estim updat
agit alzheim
agit alzheim
agit alzheim
agit alzheim
announc posit data interim-
analysi phase trial
interim analysi phase trial lumateperon
initi clinic program lumateperon depress disord
expect top line data phase trial lumateperon
associ dementia
estim primari complet date estim
expect top line data phase trial lumateperon
potenti fda advisori committe meet lumateperon
lumateperon fda action date schizophrenia
potenti file nda lumateperon bipolar depress
estim studi complet date phase trial
initi phase clinic trial
initi clinic trial
expect top line data phase trial lumateperon
adjunct therapi lithium valproat
opioid substanc
use disord pain
potenti data open-label long-term safeti switch studi
begin enrol phase trial mdd
expect complet patient enrol
estim primari complet date estim
estim primari complet date estim
request prioriti review base track
design grant lumateperon treatment
announc fda accept nda
lumateperon treatment schizophrenia
announc posit top-line data phase
studi patient parkinson diseas
last per earn call
estim primari complet date estim
announc favor result
second part open-label safeti switch studi studi
estim primari complet date estim
end
fda adcom panel jointli vote
benefit-risk profil adequ support approv
initi phase trial restorbio combin rapalog
parkinson diseas
data readout phase trial bipolar depress
potenti snda approv allergan vraylar cariprazin
top-line result phase trial minerva mdd
top-line result allergan rapastinel phase trial
initi phase trial acadia pimavanserin adjunct therapi
potenti file nda schizophrenia
estim studi complet date allergan phase trial
potenti launch allergan vraylar cariprazin
result two phase trial minerva seltorex
patient mdd adjunct therapi
compani report clinicaltri gov canaccord genuiti estim updat
announc accept snda fda
pdufa action date may
complet phase trial novel inhibitor
potenti preliminari sale result
data phase studi
result potenti busi updat
potenti nda file opicapon
top-lin data t-forc platinum studi ingrezza
potenti meet fda discuss result phase studi
potenti supplement nda file elagolix
estim studi complet date phase open-label t-forc gold
trial pediatr patient ingrezza
data pivot phase studi phase extens studi
data analysi phase trial t-forc gold ingrezza
estim studi complet date phase trial pk/pd spruce
initi larger clinic studi emalex bioscienc ecopipam
potenti initi phase trial obseva linzagolix
initi data first two patient axov scienc phase dose
escal studi sunrise-pd axo-lenti-pd
potenti top-lin data phase trial lundbeck/prexton foliglurax
potenti data myovant/takeda phase liberti trial relugolix
top-line data intec pharma ap-cd/ld phase studi
estim studi complet date phase trial safeti efficaci
estim studi complet date phase trial artist teva
potenti data myovant/takeda phase liberti trial relugolix
compani expand studi includ addit
patient optim dose flexibl conveni
receiv royalti
announc phase t-forc gold
studi valbenazin pediatr tourett syndrom fail
axon announc patient dose trial
start registr trial dipraglur
potenti data phase studi primros
potenti nda file myovant/takeda relugolix
estim studi complet date phase trial
potenti data myovant/takeda phase trial spirit
estim studi complet date phase trial diurnal chronocort
estim studi complet date phase trial
top-line result therapix bioscienc phase trial
estim studi complet date phase trial impax
estim studi complet date phase trial bayer vilaprisan
updat allergan uliprist acet
compani report clinicaltri gov canaccord genuiti estim updat
allergan receiv complet respons letter
us fda abl approv uliprist acet
nda current form allergan plan meet fda
discuss comment next step
begin enrol phase trial mdd
initi phase trial mdd patient co-morbid
estim primari complet date estim
estim primari complet date estim
announc fda extend zulresso
pdufa date final rem
nda approv post-dea drug enforc
last per earn press releas
fda adcom panel jointli vote
benefit-risk profil adequ support approv
announc accept snda fda
pdufa action date may
major depress
complet single-ascend dose trial healthi volunt
initi phase multipl ascend dose trial
top-lin result phase pivot trial
data readout phase target engag studi
data readout phase multipl ascend dose trial
data readout phase trial bipolar depress
potenti launch zulresso brexanolon iv approv
plan meet fda develop path
potenti updat addit scientif advic european medicin
agenc brexanolon
data long-term retreat studi
top-lin data phase ascend trial axs-
top-line result allergan rapastinel phase trial
potenti snda approv allergan vraylar cariprazin
initi phase trial acadia pimavanserin adjunct therapi
top-line result phase trial minerva mdd
data part phase magnolia studi marinu
full data phase amarylli studi
expect top line data phase trial
expect top line data phase trial
top-lin result phase trial vistagen
estim studi complet date allergan phase trial
potenti file nda lumateperon bipolar depress
potenti launch allergan vraylar cariprazin
result two phase trial minerva seltorex
patient mdd adjunct therapi
potenti approv janssen esketamin nasal spray us fda
result phase trial minerva seltorex patient
insomnia disord monotherapi
updat neuralstem
expect top line data phase trial lumateperon
adjunct therapi lithium valproat
compani report clinicaltri gov canaccord genuiti estim updat
announc posit result part
announc posit result interim
analysi amarylli studi
expect complet patient enrol
estim primari complet date estim
estim primari complet date estim
janssen announc submiss esketamin nasal
spray us fda
estim primari complet date estim
formal guidanc scientif advic work parti sawp
european medicin agenc ema azeliragon
interim read-out phase simplic studi
multi-region phase studi
updat clinic develop pathway azeliragon
compani report clinicaltri gov canaccord genuiti estim updat
type meet fda discuss program detail vy-aadc
updat type meet fda vy-aadc program
long-term data vy-aadc phase cohort
provid long-term data phase trial vy-aadc includ
month data patient dose posterior-trajectori method
complet phase enrol vy-aadc
estim studi complet date phase cohort trial vy-
progress research activ abbvie/tau program compani
identifi five antibodi inclus toward develop
advanc monogen form al toward
enrol pivot phase begin vy-aadc
initi human studi
top-lin data readout phase program vy-aadc
complet pivot phase enrol vy-aadc
estim studi complet date phase trial vy-aadc
potenti biolog licens applic bla submiss vy-aadc
late octob receiv addendum
fda juli written respons fda
inform compani although data phase
trial may support safeti efficaci vy-aadc
could consid bla review fda current
consid phase trial earli phase exploratori studi
updat patient cohort reach two
announc first patient dose phase
clinicaltri gov identifi month
al huntington
month enrol complet month
base phase trial
top-lin data readout phase program vy-aadc
potenti bla submiss vy-aadc
long-term data vy-aadc phase cohort
enrol statu phase trial vy-aadc
hire chief medic offic
initi data first two patient axov scienc phase dose
escal studi sunrise-pd axo-lenti-pd
compani report clinicaltri gov canaccord genuiti estim updat
base phase pivot trial
announc resign bernard
ravina continu serv clinic advisor
last earli expect end
previous guid rang per
earn releas
axon announc patient dose trial
